We have used a simplified PRESSING panel based on the available tumor molecular alterations for the cohort of patients enrolled in the PETACC-8 clinical trial, but the optimal patient selection for EGFR blocking strategies in the adjuvant setting still needs to be defined. Here, EGFR is linked to neoplasm.